261 related articles for article (PubMed ID: 32280214)
1. Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma.
Xia L; Teng Q; Chen Q; Zhang F
Int J Nanomedicine; 2020; 15():2197-2205. PubMed ID: 32280214
[TBL] [Abstract][Full Text] [Related]
2. Identification of nanobodies against hepatocellular carcinoma marker glypican-3.
Wang W; Xu C; Wang H; Jiang C
Mol Immunol; 2021 Mar; 131():13-22. PubMed ID: 33453658
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
4. Production and characterization of GPC3-N protein and its nanobody.
Lao Z; Li S; Liang J; Su J; Gong X; Cui X; Zhao S
Protein Expr Purif; 2022 Aug; 195-196():106094. PubMed ID: 35436616
[TBL] [Abstract][Full Text] [Related]
5. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
[TBL] [Abstract][Full Text] [Related]
6. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
[TBL] [Abstract][Full Text] [Related]
7. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection.
Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L
Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.
Hanaoka H; Nagaya T; Sato K; Nakamura Y; Watanabe R; Harada T; Gao W; Feng M; Phung Y; Kim I; Paik CH; Choyke PL; Ho M; Kobayashi H
Mol Pharm; 2015 Jun; 12(6):2151-7. PubMed ID: 25955255
[TBL] [Abstract][Full Text] [Related]
10. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
[TBL] [Abstract][Full Text] [Related]
11. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
[TBL] [Abstract][Full Text] [Related]
12. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
[TBL] [Abstract][Full Text] [Related]
13. GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice.
Li SQ; Lin J; Qi CY; Fu SJ; Xiao WK; Peng BG; Liang LJ
Hepatogastroenterology; 2014; 61(130):278-84. PubMed ID: 24901124
[TBL] [Abstract][Full Text] [Related]
14. Preparation of magnetic resonance probes using one-pot method for detection of hepatocellular carcinoma.
Li YW; Chen ZG; Zhao ZS; Li HL; Wang JC; Zhang ZM
World J Gastroenterol; 2015 Apr; 21(14):4275-83. PubMed ID: 25892879
[TBL] [Abstract][Full Text] [Related]
15. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
[TBL] [Abstract][Full Text] [Related]
16. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
Phung Y; Gao W; Man YG; Nagata S; Ho M
MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
[TBL] [Abstract][Full Text] [Related]
17. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.
Pan Z; Di S; Shi B; Jiang H; Shi Z; Liu Y; Wang Y; Luo H; Yu M; Wu X; Li Z
Cancer Immunol Immunother; 2018 Oct; 67(10):1621-1634. PubMed ID: 30078052
[TBL] [Abstract][Full Text] [Related]
18. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
Gao W; Kim H; Ho M
PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
[TBL] [Abstract][Full Text] [Related]
19.
Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
[TBL] [Abstract][Full Text] [Related]
20. Construction and evaluation of GPC3-targeted immunotoxins as a novel therapeutic modality for hepatocellular carcinoma.
Wu T; Song Z; Huang H; Jakos T; Jiang H; Xie Y; Zhu J
Int Immunopharmacol; 2022 Dec; 113(Pt B):109393. PubMed ID: 36375323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]